Adverse Effects and Safety of Etirinotecan Pegol - A Systematic Review in Cancer Treatment

Q: Which databases and search terms were used in the systematic review?

Studies were identified using the Scopus database, using search terms Etirinotecan Pegol and NKTR-102. Ongoing studies were also identified from clinicaltrials.gov.

Q: What studies were excluded during the review process?

The review excluded studies published in languages other than English, duplicate articles, and studies with no data.

Sep 8, 2026

Upload by Grenda

Cancer prevalence continues to rise while existing therapies may be insufficient, driving development of antitumor drugs with improved efficacy and reduced adverse effects. Polyethylene glycol (PEG) conjugation is highlighted as a technology to enhance chemotherapy safety and performance. Etirinotecan Pegol (EP/NKTR-102), the PEGylated form of irinotecan, inhibits topoisomerase I to promote cancer cell apoptosis. This systematic review evaluates EP anti-tumor evidence across cancers using Scopus and clinicaltrials.gov, excluding non-English, duplicates, and data-missing studies.

LanguageEnglish

CategoryGeneral

FormatDOCX

Pages22

Reading Time8 min

AccessFree to download

Abstract

Keywords

Introduction

Cancer epidemiology and unmet therapeutic needs

PEGylation and mechanism of Etirinotecan Pegol

Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, In Cancer Treatment: A Systematic Review Mohamad Samare-Najaf 1,2, Ali Samareh 3, Navid Jamali 1,2, Ali Abbasi 1, Cain C. T. Clark 4, Majid Jafari Khorchani 1, Fatemeh Zal 1,5,* 1 Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. 2 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran 3 Department of Biochemistry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran. 4 Centre for Intelligent Healthcare, Coventry University, CV1 5FB, U.K. 5 Infertility Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran. *Corresponding author: Fatemeh Zal Ph.D. Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Infertility Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran. E-mail address:fatemehzal@yahoo.com Tel/Fax: +98 7132303029 Abstract Due to the increasing prevalence of cancer, and the inadequacy of current therapies, the development of novel antitumor pharmaceutics, with higher efficacies and lower adverse effects, is considered a fundamental tenet of contemporary cancer management. Poly-Ethylene-Glycol (PEG) attachment is a novel pharmaceutical technology to improve the efficacy and safety of chemotherapies. Etirinotecan Pegol (EP), also known as NKTR-102, is the PEGylated form of Irinotecan (CPT-11), which causes cancer cell apoptosis by inhibiting the topoisomerase I enzyme. The present study reviews and evaluates various reports of the EP anti-tumor activity in various cancers. Studies were identified using the Scopus database, with no exclusions. The search terms included Etirinotecan Pegol and NKTR-102, which yielded 125 articles (66 and 59 articles, respectively). In addition, the clinicaltrials.gov web site was used to find ongoing studies, which resulted in the addition of two studies. Subsequently, we excluded studies that were published in languages other than English, duplicate articles, and studies with no data. This systematic review clarifies that EP possesses numerous advantages over many other medications, such as safety, efficacy, increased half-life, increased health-related quality of life, increased overall survival, increased progression-free survival, and decreasing the adverse events in the treatment of various cancers. Keywords Cancer; Chemotherapy; Drug Safety; Toxicology; Clinical Trials, Topoisomerase Inhibitors. 1. Introduction The World Health Organization (WHO) estimates that cancer is one of the most prevalent causes of, worldwide ADDIN EN.CITE Siegel201716(1)161617Siegel, Rebecca LMiller, Kimberly DJemal, AhmedinCancer statistics, 2017CA: a cancer journal for cliniciansCA: a cancer journal for clinicians7-3067120171542-4863(1). Indeed, the incidence and mortality of this disease is growing ADDIN EN.CITE Uzunalli2019104(2)10410417Uzunalli, GozdeDieterly, Alexandra MKemet, Chinyere M<

FAQs

What is Etirinotecan Pegol (EP) and how does it work?

Etirinotecan Pegol (EP), also known as NKTR-102, is the PEGylated form of irinotecan. It induces cancer cell apoptosis by inhibiting topoisomerase I.

Which databases and search terms were used in the systematic review?

Studies were identified using the Scopus database, using search terms Etirinotecan Pegol and NKTR-102. Ongoing studies were also identified from clinicaltrials.gov.

What studies were excluded during the review process?

The review excluded studies published in languages other than English, duplicate articles, and studies with no data.

Sep 8, 2026

Upload by Grenda